Videos

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration.

Sarah Enslin, PA-C, and Jennifer Geremia, PA-C, discuss the diagnosis and management of EPI, reflecting on ongoing challenges in the field.

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

King discusses real-world patient use of AI tools for mental health advice and implications for clinical conversations.

Blood discusses his recent study of the RECTIFIER AI model, highlighting its superior sensitivity and accuracy compared to physicians.

In this new episode of the Skin of Color Savvy podcast, Nambudiri speaks on-site at the AAD 2026 meeting in Denver about the clinical image collection.

Mokashi discusses 2 recent studies which he co-authored, investigating the socioeconomic impacts on health across America and the healthcare sector’s growth.

Early allergen introduction, microbiome research, and immune programming studies suggest food allergy prevention may begin during infancy.

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

Schneider discusses her analysis of the FINEARTS-HF trial, noting the apparent efficacy of finerenone regardless of sleep apnea presence.

Rezaie explains how IBS care has shifted from symptom-based treatment to targeted, mechanism-driven strategies.

Engel discusses ADAA 2026 findings identifying fear of social judgment as a distinct component of food allergy–related anxiety in adolescents.

Christensen discusses the mechanics and practical applications of the HFMS, emphasizing its success in predicting HF events based on pulmonary fluid levels.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

During this video interview at AAD 2026, Gold touches on key points made in his session titled ‘Complications of Cosmetic Procedures.’

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.

A multicenter RCT of intradialytic cycling showed a modest, nonsignificant reduction in myocardial stunning in hemodialysis patients.

Martinez describes how IBAT inhibitors are reshaping cholestatic pruritus care, with impacts on symptoms, growth, and long-term liver outcomes.